RT Book, Section
A1 Smollin, Craig
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193161552
T1 Anticoagulants Overdose
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193161552
RD 2024/04/16
AB Warfarin  and  related  compounds  (including  ingredients  of  many  commercial  rodenticides,  the  so-called  superwarfarins  such  as  brodifacoum,  difenacoum,  and  related  compounds)  inhibit  the  normal  clotting  system  by  blocking  hepatic  synthesis  of  vitamin  K–dependent  clotting  factors.  After  ingestion  of  “superwarfarins,”  inhibition  of  clotting  factor  synthesis  may  persist  for  several  weeks  or  even  months  after  a  single  dose.  DOACs  include  the  direct  thrombin  inhibitor  dabigatran  and  the  factor  Xa  inhibitors  apixaban,  edoxaban,  and  rivaroxaban.  Some  of  these,  especially  dabigatran,  are  largely  eliminated  by  the  kidney  and  may  accumulate  in  patients  with  kidney  dysfunction.